Abraxis Bioscience dismisses patent infringement complaint filed against SPARC

Explore Business Standard
Associate Sponsors

SPARC will also inform the USFDA of the dismissal of the complaint to vacate the 30-month stay.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Dec 09 2019 | 12:24 PM IST